Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.

Increased copy number involving chromosome 3q26 is a frequent and early event in cancers of the ovary, lung, head and neck, cervix, and BRCA1 positive and basal breast cancers. The p110alpha catalytic subunit of phosphoinositide-3-kinase (PI3KCA) and protein kinase Ciota (PKCiota) have previously been shown as functionally deregulated by 3q copy number increase. High-resolution array comparative genomic hybridization of 235 high-grade serous epithelial ovarian cancers using contiguous bacterial artificial chromosomes across 3q26 delineated an approximately 2 Mb-wide region at 3q26.2 encompassing PDCD10 to MYNN (chr3:168722613-170908630). Ecotropic viral integration site-1 (EVI1) and myelodysplastic syndrome 1 (MDS1) are located at the center of this region, and their DNA copy number increases are associated with at least 5-fold increased RNA transcript levels in 83% and 98% of advanced ovarian cancers, respectively. Moreover, MDS1/EVI1 and EVI1 protein levels are increased in ovarian cancers and cancer cell lines. EVI1 and MDS1/EVI1 gene products increased cell proliferation, migration, and decreased transforming growth factor-beta-mediated plasminogen activator inhibitor-1 promoter activity in ovarian epithelial cells. Intriguingly, the increases in EVI1 DNA copy number and MDS1/EVI1 transcripts are associated with improved patient outcomes, whereas EVI1 transcript levels are associated with a poor patient survival. Thus, the favorable patient prognosis associated with increased DNA copy number seems to be as a result of high-level expression of the fusion transcript MDS1/EVI1. Collectively, these studies suggest that MDS1/EVI1 and EVI1, previously implicated in acute myelogenous leukemia, contribute to the pathophysiology of epithelial ovarian cancer.

[1]  M. Matsuoka,et al.  Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. , 2004, Blood.

[2]  Bob Löwenberg,et al.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. , 2003, Blood.

[3]  G. Nucifora,et al.  EVI1 Promotes Cell Proliferation by Interacting with BRG1 and Blocking the Repression of BRG1 on E2F1 Activity* , 2003, Journal of Biological Chemistry.

[4]  D. Alberts,et al.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.

[5]  W. Mann,et al.  Investigations for Fine Mapping of Amplifications in Chromosome 3q26.3–28 Frequently Occurring in Squamous Cell Carcinomas of the Head and Neck , 2002, Oncology.

[6]  C. Lohse,et al.  Atypical protein kinase Cι is an oncogene in human non-small cell lung cancer , 2005 .

[7]  R. Wieser,et al.  Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia , 2003, Genes, chromosomes & cancer.

[8]  J. Ihle,et al.  Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. , 1990, Oncogene.

[9]  R. Wieser,et al.  The leukaemia‐associated transcription factors EVI‐1 and MDS1/EVI1 repress transcription and interact with histone deacetylase , 2001, British journal of haematology.

[10]  A. Børresen-Dale,et al.  PIK3CA mutations in advanced ovarian carcinomas , 2005, Human mutation.

[11]  E. Thompson,et al.  Evi1 is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via PI3K/AKT , 2006, Oncogene.

[12]  A. Hui,et al.  Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. , 2005, International journal of oncology.

[13]  Y. Yazaki,et al.  Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. , 1994, The Journal of biological chemistry.

[14]  A. Perkins,et al.  Identification of Binding Sites of EVI1 in Mammalian Cells* , 2005, Journal of Biological Chemistry.

[15]  A. Jauch,et al.  Breast cancer in young women (≤35 years): Genomic aberrations detected by comparative genomic hybridization , 2003, International journal of cancer.

[16]  Gordon B Mills,et al.  Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Sood,et al.  MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1 , 1999, Leukemia.

[18]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[19]  April 1 , 1974 .

[20]  S. Clarke,et al.  The Novel Human Protein Arginine N-Methyltransferase PRMT6 Is a Nuclear Enzyme Displaying Unique Substrate Specificity* , 2002, The Journal of Biological Chemistry.

[21]  J. Inazawa,et al.  Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. , 2003, Cancer research.

[22]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[23]  K. Irie,et al.  The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3 , 1998, Nature.

[24]  F. Solé,et al.  Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. , 2004, Cancer genetics and cytogenetics.

[25]  S. Ogawa,et al.  Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP , 2005, Oncogene.

[26]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[27]  D. Palmieri,et al.  Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. , 2004, Experimental cell research.

[28]  M. Matsuoka,et al.  Aberrant expression of the MEL 1 S gene identified in association with hypomethylation in adult T-cell leukemia cells , 2004 .

[29]  J. Fridlyand,et al.  Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. , 2004, The American journal of pathology.

[30]  D. Xie,et al.  Oncogenic Role of eIF-5A2 in the Development of Ovarian Cancer , 2004, Cancer Research.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  B. Löwenberg,et al.  Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. , 2003, Experimental hematology.

[33]  N. Yang,et al.  Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. , 2006, Cancer research.

[34]  A. Lash,et al.  Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.

[35]  B. Wullich,et al.  Novel amplification unit at chromosome 3q25–q27 in human prostate cancer , 2000, The Prostate.

[36]  D. Meijer,et al.  Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice , 2000, Leukemia.

[37]  G. Nucifora,et al.  EVI1 and hematopoietic disorders: history and perspectives. , 2006, Gene.

[38]  N. Nomura,et al.  SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. , 2001, Biochemical and biophysical research communications.

[39]  Marcel J T Reinders,et al.  Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.

[40]  Ajay N. Jain,et al.  Assembly of microarrays for genome-wide measurement of DNA copy number , 2001, Nature Genetics.

[41]  G. Nucifora,et al.  The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator , 1997, Leukemia.

[42]  N. Tanaka,et al.  Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. , 2000, Cancer genetics and cytogenetics.

[43]  J. Shah,et al.  The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  I. Campbell,et al.  PIK3CA Mutations in Ovarian Cancer , 2005, Clinical Cancer Research.

[45]  B. Wullich,et al.  Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer , 1999, The Prostate.

[46]  J. Inazawa,et al.  TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Chadwick,et al.  Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. , 2001, Genes & development.